

AMENDMENT

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows.

IN THE CLAIMS:

Kindly amend the claims, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, to read as follows:

1-39. (Cancelled)

40. (Previously Presented) A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group comprising:

psoriasis, acne vulgaris, actinic ketatosis, solar keratosis, squamous carcinoma *in situ*, ichthyoses, hyperkeratosis and disorders of keratinisation;
consisting essentially of administering, to a patient in need thereof, an inhibitor of the retinoic acid biosynthetic pathway, wherein said inhibitor is carbenoxolone.

41. (Previously Presented) A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group comprising:

psoriasis, acne vulgaris, and hyperkeratosis;
consisting essentially of administering, to a patient in need thereof, an inhibitor of the retinoic acid biosynthetic pathway, wherein said inhibitor is carbenoxolone.

42. (Previously Presented) A method of treating psoriasis consisting essentially of administering, to a patient in need thereof, an inhibitor of the retinoic acid biosynthetic pathway, wherein said inhibitor is carbenoxolone.

43. (Previously Presented) The method of claim 40, wherein the disorder of keratinisation is Darrier's disease.

44. (Previously Presented) A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group comprising:

psoriasis, acne vulgaris, actinic ketatosis, solar keratosis, squamous carcinoma *in situ*, ichthyoses, hyperkeratosis and disorders of keratinisation;
comprising topically administering to skin of a patient in need thereof, an inhibitor of the retinoic acid biosynthetic pathway, wherein said inhibitor is carbenoxolone.

45. (Previously Presented) A method of treating a hyperproliferative disease of the skin subject to treatment by inhibition of the retinoic acid biosynthetic pathway, said disease selected from the group comprising:

psoriasis, acne vulgaris, and hyperkeratosis;
comprising topically administering to skin of a patient in need thereof, an inhibitor of the retinoic acid biosynthetic pathway, wherein said inhibitor is carbenoxolone.

46. (Previously Presented) A method of treating psoriasis comprising topically administering to skin of a patient in need thereof, an inhibitor of the retinoic acid biosynthetic pathway, wherein said inhibitor is carbenoxolone.

47. (Previously Presented) The method of claim 44, wherein the disorder of keratinisation is Darrier's disease.

48. (New) A method of dreating a disease selected from psoriasis, acne vulgaris, actinic keratosis, solar keratosis, squamous carcinoma *in situ*, ichthyoses, hyperkeratosis and disorders of keratinization, comprising administering carbenoxolone to a patient in need thereof.

49. (New) A method of treating a disease selected from psoriasis, acne vulgaris and hyperkeratosis, comprising administering carbenoxolone to a patient in need thereof.

50. (New) A method of treating psoriasis comprising administering carbenoxolone to a patient in need thereof.

51. (New) The method of claim 48 wherein the disorder of keratinization is Darrier's disease.